medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2020, Número 2

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2020; 31 (2)


Prevalencia y perfil clínico-terapéutico de la fibrilación auricular en consultorios de cardiología privados del noreste de México

Solís OCA, Ramírez RSA, Carrillo PMA, Solís SJM

Idioma: Inglés [English version]
Referencias bibliográficas: 23
Paginas: 40-48
Archivo PDF: 440.39 Kb.


RESUMEN

Introducción: La prevalencia de fibrilación auricular (FA) en México es desconocida. Objetivos: Documentar la prevalencia de FA y su perfil clínico-terapéutico. Métodos: Estudio transversal, en tres consultorios privados de cardiología; en 337 de 8,999 expedientes clínicos, la FA fue documentada. Resultados: Prevalencia de FA, 3.74%; permanente 56.0%, paroxística 28.4%, persistente 15.7%. FANV 94.06%. Edad, 74 ± 12.89 años, mujeres 52.22%, hipertensión, 74.18%, tabaquismo, 36.79%, alcoholismo 35.01%, diabetes tipo 2, 30.56%. El grupo CHA2DS2-VASc ≥ 2, comparado al 0-1, recibió más anticoagulación oral ACO (31.88 vs 8.333%) y nuevos anticoagulantes orales (NAO) (53.31 vs 13.33%) p ‹ 0.01 para ambos. En pacientes de 60-75 años, se utilizaron más ACO en el grupo CHA2DS2-VASc ≥ 2 respecto al 0-1 (34.89 vs 6.25%) p = 0.0004 y NOA (54.16 vs 0%) p ‹ 0.01. El grupo CHADS ≥ 2 comparado al 0-1, utilizó más ACO (33.6 vs 18.8%) NAO (55.17 vs 34.11%) p ‹ 0.01 para ambos y antagonistas de la vitamina K (AVK) (12.06 vs 3.5%) p = 0.004. El grupo CHA2DS2-VASc ≥ 2 vs 0-1 tuvo más mujeres que hombres (95.03 vs 85.9%), recibió más diuréticos (57.49 vs 13.33%), antagonistas de los receptores de mineralocorticoides (ARM) (27.52 vs 0%) y bloqueadores de los receptores de angiotensina 2 (BRA 2) (55.40 vs 16.66%) p ‹ 0.01 para todos. Conclusión: En nuestros pacientes la FA se caracteriza por tener un perfil de alto riesgo cardiovascular, alcoholismo, senilidad y predominio de mujeres, con una prevalencia (3.74%) similar a la de otros países occidentales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 2017; 69: 1968-1982.

  2. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213-220.

  3. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4 (1): e001486.

  4. Lip GY, Bawden L, Hodson R, Rutland E, Snachtfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population: the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 1998; 65: 187-192.

  5. González-Hermosillo JA, Márquez MF, Ocampo-Peña S. Design of an atrial fibrillation and embolic risk registry in México: CARMEN-AF. Arch Cardiol Mex. 2017; 87 (1): 5-12.

  6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS focused update if the 2014 guideline for management of patients with atrial fibrillation: a report of American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019; 16 (8): e66-e93.

  7. Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019; 9 (4): e026645.

  8. Rodriguez Diez G, Márquez MF, Iturralde P, Molina L, Pozas G, Cordero Cabra A et al. Joint Mexican Position document on the treatment of atrial Fibrillation. Endorsed by: Mexican National Association of Cardiologist (ANCAM), Mexican Electrophysiology and Pacing Society (SOMEEC) and Mexican Society of Cardiology (SMC). Cardiovasc Metab Sci. 2019; 30 (3): 91-99.

  9. Steinberg BA, Gaor H, Shrader P, Pieper K, Thomas L, Camm AJ et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF 1, AND ORBIT-AF II, registres. Am Heart J. 2017; 194: 132-140.

  10. Jackson LR, Peterson ED, Okeagu E, Thomas K. Review of race/ethnicity in non vitamin K antagonist oral anticoagulantes clinical trials. J Thromb Thrombolysis. 2015; 39 (2): 222-227.

  11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981-992.

  12. Amponsah MK, Benjamin EJ, Magnani JW. Atrial fibrillation and race - A contemporary review. Curr Cardiovasc Risk Rep. 2013; 7 (5). doi: 10.1007/s12170-013-0327-8.

  13. Martínez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL et al. XANTUS-EL: a real-world prospective, observational study of patients treated with rivaroxabán for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J. 2018; 70 (4): 307-313.

  14. Lara-Vaca S, Cordero Cabra A, Martínez-Flores E, Iturralde Torres P. Registro Mexicano de Fibrilación Auricular (ReMeFa). Gac Med Mex. 2014; Suppl 1: 48-59.

  15. Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients and racial minorities in the randomized trial used for cardiovascular guidelines. JAMA Int Med. 2014; 174 (11): 1868-1870.

  16. Simmons A, Falbe J, Vacek J. Coronary artery disease in women: a review and update. Rev Cardiovasc Med. 2011; 12 (2): e84-e93.

  17. Li YM, Jiang C, He L, Li XX, Hou XX, Chang SS et al. Sex differences in presentation, quality of life, and treatment in Chinese atrial fibrillation patients: insights from the China Atrial Fibrillation Registry study. Med Sci Monit. 2019; 25: 8011-8018.

  18. García M, Mulvagh SL, Merz NB, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016; 118 (8): 1273-1293.

  19. Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB et al. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2017; 14 (2): 113-124.

  20. Cheng EY, Kong MH. Gender differences of thromboembolic events in atrial fibrillation. Am J Cardiol. 2016; 117 (6): 1021-1027.

  21. Volterrani M, Iellamo F, Rosano G, Guarini P, Pusineri E, Bonassi S et al. Anticoagulation in “real world” patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Int J Cardiol. 2013; 168 (5): 4729-4733.

  22. Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K et al. Treatment patterns in anticoagulant therapy in patients with newly diagnoses atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Act Cardiol. 2019; 74 (4): 309-318.

  23. Bassand JP, Acceta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA et al. Two year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37 (38): 2882-2889.




2020     |     www.medigraphic.com